Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 5/20 | 0.51 |
| ▸ | F2 | P00734 | 3/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365602 | 0.85 | L3MBTL1 (0.70) | KMOL3MBTL1NPC1RAB9APPARG | |
| SCHEMBL13366031 | 0.83 | F10 (0.54) | KMOF10F2L3MBTL1KMT2A | |
| SCHEMBL26606507 | 0.82 | AKR1C3 (0.57) | KMOAKR1C3MRGPRX4F10F2 | |
| SCHEMBL30576789 | 0.82 | AKR1C3 (0.57) | KMOAKR1C3MRGPRX4F10F2 | |
| SCHEMBL4324193 | 0.81 | PARP15 (0.47) | KMOLOXL2NR4A2KMT2A | |
| SCHEMBL5582337 | 0.79 | AKR1C3 (0.70) | KMOAKR1C3MRGPRX4F10F2 | |
| SCHEMBL8866023 | 0.78 | RAB9A (0.43) | L3MBTL1RAB9AKMT2A | |
| SCHEMBL1168418 | 0.78 | PPARG (0.62) | KMOAKR1C3MRGPRX4F10F2 | |
| SCHEMBL10637016 | 0.78 | CYP1A2 (0.50) | KMT2A | |
| SCHEMBL5710617 | 0.77 | BCAT2 (0.60) | L3MBTL1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2362730-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010059618-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HSD11B1, HSD17B11, HSD3B1 | KMO 2321/4885AKR1C3 173/4885MRGPRX4 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.